The global medical cannabis market is set to reach US$148.9 billion by 2031, fueled by regulatory reforms and expanding ...

The Trump administration is re-evaluating its stance on federal law 922(g)(3), which impacts medical cannabis gun rights.

The US Justice Department's Schedule III reclassification for medical cannabis products is revitalizing investor interest.

The US House has passed the 2026 Farm Bill, retaining a ban on intoxicating hemp products. This decision creates significant ...

A UC Berkeley study reveals licensed cannabis farms are the most effective deterrent to unlicensed cultivation in California, ...

Explore how the US reclassification of cannabis is poised to drive IPOs and private funding for companies developing cannabis ...

Discover how industrial hemp construction, particularly hempcrete, is revolutionizing the building industry. Learn about its ...

Medical cannabis businesses face a complex 60-day window for DEA registration, navigating potential legal admissions of past ...

Vireo Growth's acquisition of Fluent via a debt-for-stock deal significantly reshapes the medical cannabis market in Florida, ...

Federal marijuana rescheduling is prompting renewed interest from pharmaceutical firms and investors. Discover how this ...

Australia is on the cusp of a vital change in drug driving enforcement with new cannabis breathalyser technology. Explore how ...

Explore the potential for Nebraska medical cannabis laws to gain protection from federal interference. This analysis delves ...